32 related articles for article (PubMed ID: 8588767)
1. Evaluate the in vitro effect of anthracycline and alkylating cytophosphane chemotherapeutics on dopaminergic neurons.
Desai D; Majrashi M; Pathak S; Almaghrabi M; Liu K; Pondugula SR; Tiwari AK; Babu RJ; Deruiter J; Dhanasekaran M
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2074. PubMed ID: 38627904
[TBL] [Abstract][Full Text] [Related]
2. Influence of the Sense of Coherence, the Doctor-Patient Relationship, Optimism and Non-Haematological Adverse Reactions on Health-Related Quality of Life in Patients with Breast Cancer.
Prieto-Callejero B; Rivera F; Andrés-Villas M; Gómez-Salgado J
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766496
[TBL] [Abstract][Full Text] [Related]
3. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.
Abraham R; Basser RL; Green MD
Drug Saf; 1996 Dec; 15(6):406-29. PubMed ID: 8968695
[TBL] [Abstract][Full Text] [Related]
4. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
5. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Basser RL; Abraham R; To LB; Fox RM; Green MD
Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Bonneterre J; Tubiana-Hulin M; Catimel G
Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
[TBL] [Abstract][Full Text] [Related]
7. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer.
Levi JA; Beith JM; Snyder RD; Tattersall MH; Bell D; Wheeler H
Aust N Z J Med; 1995 Oct; 25(5):474-8. PubMed ID: 8588767
[TBL] [Abstract][Full Text] [Related]
10. Role of epirubicin in advanced breast cancer.
Conte PF; Gennari A; Landucci E; Orlandini C
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
[TBL] [Abstract][Full Text] [Related]
11. Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness.
Bergh J
Breast; 2003 Dec; 12(6):529-37. PubMed ID: 14659131
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
